Introduction
Recent evidence supports the view that inflammatory bowel disease (IBD) is caused by genetically determined dysregulation of the mucosal immune response to luminal antigens derived from the intestinal microflora. [1] [2] [3] [4] Activated T lymphocytes mediating inflammation have been identified for the two phenotypes of IBD. Activated Th1 lymphocytes incline more toward the proinflammatory cytokines, which include tumor necrosis factor-a (TNF-a), interferon-g (IFN-g), interleukin-1 (IL-1) and IL-12. The activated lymphocytes in ulcerative colitis exhibit increased levels of IL-5, IL-6 and transforming growth factor-b (TGF-b).
Interleukin-10 plays a very important role in the immunological balance of the mucosal immune system. It acts by inhibiting the production of proinflammatory cytokines from activated macrophages and, thus inhibits antigen presentation and effector functions. IL-10 is also known to inhibit chemokines, including monocyte inflammatory protein-1a (MIP-1a) and eotaxin, along with inhibition in the expression of inducible nitric oxide synthase and cyclooxygenase-2 in macrophages. [6] [7] [8] Several researchers have demonstrated the usefulness of IL-10 in suppression of inflammation in a trinitrobenzenesulfonic acid (TNBS)-induced acute colitis animal model. 6, 9, 10 Systemic administration of recombinant IL-10 has been investigated in several small clinical trials with limited success. 11 Nakase et al. 12 administered IL-10 protein in gelatin microspheres to IL-10/(À/À) knockout mice and showed some efficacy. Genetically engineered Lactococcous lactis have also been developed for local delivery of IL-10 protein in the intestinal lumen upon oral administration. 13 Local delivery of plasmid DNA encoding for IL-10 has also been reported and much of the effort has been made with the use of viral vectors, including replication-deficient adenoviruses. 6, 9, 10, 14 Although viral vectors have been used successfully in preclinical studies, the potential for toxicity of viruses, especially upon chronic administration, is a major concern when it comes to translation of this experimental strategy into clinical reality. 15, 16 We and others [17] [18] [19] have, therefore, focused on development of safe and effective nonviral gene delivery systems. Among several examples of nonviral vectors, polymeric gene delivery systems have received significant attention. [17] [18] [19] [20] [21] [22] [23] In previous studies, we have described the formulation development, characterization, optimization and preliminary in vivo transfection of reporter plasmids upon oral administration of nanoparticles-in-microsphere oral system (NiMOS) formulations in animal models. 24, 25 NiMOS is a biodegradable and biocompatible polymer-based microparticle system capable of plasmid DNA delivery and local transfection upon oral administration. This delivery system is specifically engineered for oral gene therapy, where the DNAencapsulated gelatin nanoparticles can be released in the intestine from poly(epsilon-caprolactone) matrix due to lipase-induced degradation. Once released, the nanoparticles can be endocytosed by the cells of the intestinal lumen to afford efficient transfection and transgene expression. The solvent displacement technique employed to formulate type B gelatin nanoparticles encapsulating plasmid DNA has been previously optimized and reported by our laboratory. 26, 27 To illustrate the utility of type B gelatin nanoparticles for systemic gene therapy, we have administered reporter and therapeutic (sFlt-1 expressing) plasmid DNA in poly (ethylene glycol)-modified nanoparticles for efficient and sustained transgene expression and antiangiogenic therapeutic efficacy in solid tumor models. 19, [28] [29] [30] To further evaluate the potential of NiMOS in oral therapeutic gene therapy, in this study, we show local transfection of IL-10 and therapeutic efficacy in TNBSinduced acute colitis model developed in Balb/c mice. Figure 1 shows the cross-sectional schematic of NiMOS and the scanning electron microscopy (SEM) images obtained for gelatin nanoparticles. The SEM image confirmed the formation of small spherical type B gelatin nanoparticles with encapsulated plasmid DNA expressing murine IL-10. The average particle diameter of the resulting microspheres, as determined by Coulter analysis using Multisizer 3 and by SEM, was in the range of 2-5 mm. Figure 1 also shows an inset of a NiMOS showing the spherical nature of NiMOS and smooth surface resulting from encapsulation of gelatin nanoparticles within the poly(epsilon-caprolactone) matrix. PicoGreen dsDNA fluorescent assay was used to quantitate the capacity and efficiency of plasmid DNA encapsulation in gelatin nanoparticles and in NiMOS. The plasmid DNA encapsulation efficiency in gelatin nanoparticles was greater than 93% at 0.5% (w/w) concentration. When DNA-containing gelatin nanoparticles were further encapsulated in NiMOS, the final DNA loading efficiency was found to be approximately 46% as determined by DNA extraction using dichloromethane and protease digestion of gelatin nanoparticles to release encapsulated DNA.
Results

IL-10-expressing plasmid DNA-encapsulated NiMOS
Local IL-10 transfection upon oral administration Assessment of plasmid composition and purity. The pORF5-mIL-10 plasmid, purchased from InvivoGen (San Diego, CA, USA) in transformed Escherichia coli, was further amplified and purified from culture using the Plasmid Giga purification kit (Qiagen, Valencia, CA, USA). The plasmid composition and purity, as assessed by agarose gel electrophoresis, is shown in Figure 2a . Lane 1 of the agarose gel is 2-10 kbp supercoiled ladder, lane 2 is intact plasmid DNA (that is, pORF5-mIL-10), lane 3 is 1-10 kbp linear plasmid ladder, lane 4 is 100 kbp ladder and lane 5 is pORF5-mIL-10 plasmid DNA treated with endonucleases NcoI and NheI. The size of pORF5-mIL-10 is 3.7 kbp and the band seen in Figure 2a in lane 2 is between 3 and 5 kbp, suggesting that the plasmid DNA is pORF5-mIL-10. To further confirm the purity of the isolated plasmid DNA, it was further incubated with restriction enzymes NcoI and NheI, which resulted in the formation of two fragment of plasmid DNA that were about 3.1 kbp and 570 bp. Lane 5 in Figure 2a shows two bands representing 3.1 kbp and the other smaller band was between 500 and 600 bp, thus further confirming the composition of pORF5-mIL-10. Oral IL-10 gene therapy for IBD MD Bhavsar and MM Amiji administration of the plasmid DNA in NiMOS. Figure 2b shows the results of quantitative RT-PCR analysis to examine murine IL-10 mRNA transcript levels in the large intestine of control and transfected animals. IL-10-expressing plasmid DNA when encapsulated in NiMOS showed highest levels of mRNA expression.
Measurement of transfected IL-10 levels by ELISA.
Following oral administration of pORF5-mIL-10 at 100 mg dose per mice in gelatin nanoparticles and in NiMOS to colitis-induced mice, the levels of murine IL-10 expression was determined in the inflamed colon 4 days post-administration. Figure 2c shows murine IL-10 protein levels in the large intestine of the control and treated animals as determined by ELISA. The group receiving gelatin nanoparticles encapsulating pORF5-mIL-10 as treatment showed similar levels of colonic IL-10 as seen for the saline group. Figure 2c also Therapeutic efficacy studies were performed on various treatment groups. In this study, we looked at many different parameters ranging from expression of inflammatory cytokines and chemokines, body weight changes, macroscopic clinical activity score, as well as histological analysis of large intestine and tissue myeloperoxidase (MPO) activity.
Proinflammatory cytokine and chemokine profiling. The expression profile of proinflammatory cytokines and chemokines upon successful murine IL-10 transfection are reported in Figure 3 . Figures 3a and b shows the results obtained for IL-1a and IL-1b. During colitis the levels of both these proinflammatory cytokines were raised to above 150 pg mg À1 of total protein. A significant decrease to about 20 and 10 pg mg À1 of total protein for IL-1a and IL-1b, respectively, was observed for the colitis group receiving NiMOS treatment. The colitis group receiving plasmid DNA gelatin nanoparticles did not show any significant decrease in the levels of both of these cytokines, where the values remained above 100 pg mg À1 for both. We also observed a decrease in the levels of other proinflammatory cytokines, such as IFN-g, TNF-a and IL-12 in the NiMOStreated group, as seen in Figures 3c-e, respectively. In contrast, the group that received DNA encapsulated in Oral IL-10 gene therapy for IBD MD Bhavsar and MM Amiji gelatin nanoparticles did not show any decrease in the levels of these proinflammatory cytokines. This is due to the fact that gelatin nanoparticles were not able to transfect the cells at the site of inflammation causing no change in the levels of IFN-g and subsequently in levels of TNF-a and IL-12. Upon induction of colitis the values of TNF-a and IL-12 were raised to about 180 and 20 pg mg À1 of total protein, respetively. Whereas the normal values for these cytokines as determined by ELISA were found to be 8 pg mg À1 of total protein for IL-12 and 15 pg mg À1 of total protein for TNF-a. Similar levels were observed for colitis group receiving with gelatin nanoparticles as treatment. We observed a significant decrease in the levels of these cytokines for colitis group receiving NiMOS to about 6.5 pg mg À1 for IL-12 and 14 pg mg À1 for TNF-a. Figure 3f shows the expression levels of different proinflammatory chemokines. We observed a decrease in the levels of two chemokines, monocyte chemotactic protein 1 (MCP-1) and MIP-1a, upon increase in the IL-10 levels at the site of inflammation, Figure 3f . The baseline of MCP-1 and MIP-1a as determined by ELISA were about 80 and 9 pg mg À1 of total protein, respectively. These levels were increased to 1600 and 850 pg mg À1 for MCP-1 and MIP-1a, respectively, for the colitis group receiving saline and gelatin nanoparticles. Upon administration of NiMOS formulation, these levels were brought back to 550 and 50 pg mg À1 of total protein for MCP-1 and MIP-1a, respectively. We did not observe any change in the levels of Regulated on Activation, Normal T Expressed and Secreted (RANTES) in the colitis or upon treatment with IL-10-expressing plasmid DNA in any of the formulations.
Body weight changes and clinical activity score. To further confirm the therapeutic benefits that can be achieved with IL-10 oral gene therapy, change in body weight of colitis-induced mice after different treatments was examined. Figures 4a and b shows the percent change in body weight of mice upon acute colitis induction and after administration of various treatments. Oral IL-10 gene therapy for IBD MD Bhavsar and MM Amiji Figure 4a shows change in body weight over the whole period of study, and Figure 4b shows the change in body weight after day 4, which corresponds to administration of the second dose of TNBS. NiMOS formulation showed a considerable increase in transfection at the site of inflammation, which resulted in significant gain in body weight of mice starting from 2 days post-administration of the formulation, and complete restoration of body weight was observed 4 days post-administration. The group receiving saline and plasmid DNA in gelatin nanoparticles, on the other hand, showed significant loss in body weight upon colitis induction and formulation administration. The loss in body weight observed in case of DNA-encapsulated gelatin nanoparticles was as high as 25% of the original body weight after 4 days postadministration. Figure 4c shows the results of clinical activity scored according to the criteria mentioned before. The clinical activity score of the disease for NiMOS group returned back to normal, less than 1 on day 4 post-administration of the formulation, whereas high activity levels, greater than 3 similar to colitis group were observed for group administered with gelatin nanoparticles.
Lastly, the colon length and colon weight were the other two parameters that were observed and are reported in Figures 4d and e, respectively. We observed a significant decrease in colon length and colon weight upon colitis induction, which was also observed for gelatin nanoparticle treatment group. For the NiMOS treatment group, we observed an increase in the length and weight of the colon back to normal, which was a significant gain when compared to colitis and gelatin nanoparticles group. The results of this study showed a reduction in colon length during colitis to about 6 cm and the weight was reduced to about 200 mg. The colitis group treated with NiMOS showed a significant (Po0.01) increase in both colon length (9 cm) and weight back (B300 mg) to baseline level.
Tissue histological evaluation and MPO activity. To further demonstrate the efficacy of locally expressed IL-10 in suppressing inflammation in an acute colitis model, the large intestinal tissue cryosections were stained with hematoxylin and eosin and observed with a bright-field microscope. Figure 5a shows the changes occurring at the cellular level upon colitis induction and Oral IL-10 gene therapy for IBD MD Bhavsar and MM Amiji treatment of inflammation with IL-10 gene therapy. As can be seen, the naive colon shows very good mucosal architecture including the presence of goblet cells. In contrast, the large intestinal colitis-induced tissue showed classical features of inflammation, including thickening of luminal wall, loss of mucosal architecture and cellular infiltration. These features were also observed in the group administered with pORF5-mIL-10 in gelatin nanoparticles confirming earlier observation of lack of IL-10 transfection and absence of any antiinflammatory effect with gelatin nanoparticles alone. In contrast, colitis-bearing animals treated with plasmid DNA in NiMOS showed a significant decrease in inflammation with the histology of colon almost restoring back to that the native state in such a short-time period.
Furthermore, we determined the MPO activity levels as a marker of neutrophil infiltration and inflammation. As shown in Figure 5b , there was a significant increase in MPO activity levels, about 30 MPO activity per gram of tissue, were observed upon induction of acute colitis in Balb/c mice. The MPO activity upon treatment with transfected IL-10 using NiMOS formulations was significantly reduced (Po0.005) to about 2 MPO activity per gram of tissue and was comparable to the enzyme activity in the normal noncolitis colon. In contrast, the tissue MPO activity levels were significantly higher in colitis group treated with pORF5-mIL-10 encapsulated in gelatin nanoparticles group. This result supports our previous findings obtained from histological analysis of the large intestine specimens, whereby high levels of cellular infiltration and inflammatory activity was observed in control and gelatin nanoparticle-treated animals.
Discussion
In this study, we describe the use of NiMOS for delivery of therapeutic plasmid DNA encoding murine IL-10 in TNBS-induced acute colitis model developed in Balb/c mice ( Figure 2) . The RT-PCR analysis results showed very high levels of transcription of transgene (murine IL-10), as determined by the mRNA levels, for the colitis group administered with NiMOS treatment. The high levels seen for this group can be attributed to the murine IL-10 transgene, as such high levels were not observed for other treatment groups, including gelatin nanoparticles. Some what high levels of IL-10 mRNA, compared to noncolitis group, was observed for colitis groups with saline and gelatin nanoparticles as treatment but this could be a compensatory response due to induced colitis. The ELISA results for IL-10 were in good correlation with the RT-PCR data. A high level of murine IL-10 protein was observed for NiMOS treatment group, which would have generated from high local levels of murine IL-10 mRNA levels observed during the RT-PCR analysis. We observed relatively higher levels of IL-10 in the colitis group administered with saline alone as compared to naive animals. This increase in IL-10 level has been suggested to be compensatory IL-10, which is expressed in response to the induced colitis. 6 The ELISA results along with the RT-PCR results clearly demonstrate the high transfection ability of NiMOS formulation upon oral administration. In addition to the ability of NiMOS to protect the payload from the gastrointestinal barriers, such a high level of transfection can be a result of exposure of NiMOS to the underlying cells of the gastrointestinal tract in case of colitis.
The therapeutic benefits that can be obtained with high local levels of murine IL-10 in colitis-induced mice are shown in Figure 3 . As reported for Crohn's disease, an upregulation in the expression of Th-1-derived cytokines, such as IL-1, IL-12, IFN-g and TNF-a, was observed in our TNBS-induced murine colitis model. Crohn's disease is characterized by an increase in activation of transcription factor nuclear factor-kB with downstream effects on cytokine production, such as TNF-a and immune regulation. 31, 32 The NiMOS treatment showed a 10-fold decrease in local levels of TNF-a. We also observed similar reduction in the levels of other proinflammatory Th-1-derived cytokines, such as IL-12, IL-a, IL-1b and IFN-g. IL-10 has been known for its role as a cytokine synthesis inhibitor and is also known to modulate expression levels of Th-1-derived cytokines. 4, 6 Along with reduction in levels of proinflammatory cytokines, there was also significant reduction in certain chemokines, such as MCP-1and MIP-1a. A direct action of IL-10 on these chemokines has not been reported, but these chemokines are known to modulate inflammatory conditions by regulating immune cell infiltration at the disease site. To this effect, systemic administration of MIP-1a has been reported to exacerbate IBD in mouse models. 33 Reduction in the levels of Th-1-derived cytokines, such as IFN-g, IL-1, IL-12 and TNF-a, due to the presence of IL-10 could have resulted in the cessation of ongoing inflammatory process at the disease site.
In contrast, higher levels of inflammatory cytokines and chemokines, comparable with colitis group receiving saline treatment, were observed in animals treated with DNA encapsulated in gelatin nanoparticles. This could be due to the poor stability of gelatin nanoparticles in protease-rich gastrointestinal fluid leading to premature release and degradation of the DNA. We did not observe any changes in RANTES levels for any of the treatment groups. Previously, high levels of RANTES have been reported in chronic murine models of TNBS-induced colitis. 34 As we used an acute TNBS-induced colitis model, such an increase in RANTES levels were not observed during the course of this study.
The reduction in the local burden of proinflammatory cytokines and chemokines caused by excess IL-10 upon administration of NiMOS treatment resulted in reversal of experimental colitis, which was reflected in the body weight changes, macroscopic disease activity score and colon morphology (Figure 4 ). Upon induction of colitis using a hydroalcoholic TNBS solution, the animals start losing body weight and this can be used successfully to determine the therapeutic benefits that can be obtained from various treatments. 35 Among all the treatment groups, only the animals in colitis group administered with NiMOS formulation showed weight gain back to the original 4 days after the loss of more than 10% of their original body weight upon administration of second dose of TNBS The NiMOS treatment not only reversed the loss in body weight, but also caused a reduction in the disease activity score. The disease state also caused a decrease in colon length and colon weight in mice and these values reversed back to baseline upon administration of NiMOS treatment to colitis mice. The
Oral IL-10 gene therapy for IBD MD Bhavsar and MM Amiji significant decrease in disease activity for the NiMOS treatment group can only be attributed to the increased local levels of IL-10 upon treatment. The IL-10 levels were seen to reduce the burden of proinflammatory cytokines in the colon and led to a reduction in the process of stimulation of the immune system maintaining the disease state. Lastly, we studied tissue histology along with determination of tissue cellular infiltration using MPO activity ( Figure 5 ). The hematoxylin and eosin were used to stain the tissue cryosections of colon obtained from different treatment groups. The microscopic evaluation of noncolitis tissue section revealed a normal mucosal architecture along with presence of goblet cells. Upon induction of colitis, the composure of colon was compromised accompanied with loss in the protective epithelial layer and heavy infiltration of immune cells. The lack in ability of gelatin nanoparticles to successfully deliver the transgene to the cells of the colon inflicted with colitis resulted in no change in the ongoing inflammatory process occurring in the colon. For the NiMOS treatment group the colon architecture was reversed back to normal. The high local levels of IL-10 were not only able to reduce the levels of inflammatory cytokines and chemokines and cellular infiltration, but this in turn led to proliferation of normal tissue cells causing a reversal in the disease state. The reduction in cellular infiltration for NiMOS group was further demonstrated by MPO activity which was significantly lower, almost back to normal levels, where as it remained very high for colitis group treated with saline and gelatin nanoparticles. This study further indicates that IL-10 plays a crucial role in inflammation and can also result in reduction of inflammation by acting as an immunomodulatory cytokine. IBD in humans is a chronic disease involving cycles of remission and relapse upon treatment with many different kinds of drugs and steroidal molecules. Gene therapy has the potential to provide prolonged remission to patients suffering from this chronic disease mediated by the interplay between pro-and anti-inflammatory cytokines at the disease site.
Materials and methods
Preparation of plasmid DNA-encapsulated NiMOS
Nanoparticles-in-microsphere oral system were prepared using murine IL-10-expressing plasmid DNA (pORF5-mIL-10)-encapsulated type-B gelatin nanoparticles in poly(epsilon-caprolactone) matrix to form 2-5 mm sized microspheres as previously described. 24, 25 Briefly, 10 mg of plasmid DNA-encapsulated gelatin nanoparticles were suspended in distilled deionized water. This suspension was added to 2.0 ml of dichloromethane containing 0.5% (w/v) poly(epsilon-caprolactone) and homogenized at room temperature. The formed primary emulsion was added to an external aqueous phase containing 0.1% (w/v) poly(vinyl alcohol) and further homogenized to obtain a stable secondary emulsion. The formed double emulsion was stirred to evaporate the dichloromethane followed by purification by centrifugation and finally lyophilized. The microparticle formulation was obtained by allowing dichloromethane to evaporate at room temperature, washing off the excess poly(vinyl alcohol) by repeated centrifugation, and freeze-drying to obtained free-flowing powder.
Development of TNBS-induced acute colitis model in Balb/c mice
The animal studies described below were performed according to the experimental protocol approved by the Institutional Animal Care and Use Committee at Northeastern University (Boston, MA, USA). Female Balb/c mice, 8-10 weeks old, weighing approximately 20 g, were purchased from Charles River Laboratories (Wilmington, MA, USA). Before the model development, all mice were anesthetized by intraperitoneal injection of ketamine-xylazine. Following anesthesia, 2.5 mg of TNBS dissolved in 100 ml of 40% (v/v) ethanol solution was administered rectally to the anesthetized mice twice on day 0 (at the start of the experiment) and at day 4 using a 1.2 mm polyethylene catheter. Acute colitis development was confirmed by measurements of weight loss, stool consistency, rectal bleeding and tissue histology.
Oral administration of IL-10 plasmid encapsulated in NiMOS
When acute colitis was confirmed in Balb/c mice after administration of the two TNBS doses, the animals were fasted for 24 h and divided into control and treatment groups. In the treatment group, conscious animals received NiMOS encapsulated with pORF5-mIL-10 at a dose of 100 mg by oral gavage. Additionally, gelatin nanoparticles encapsulated with pORF5-mIL-10 was administered to another group at a dose of 100 mg and served as a control. Control animals did not receive any treatment. Changes in the body weight was measured periodically. In addition, after 4 days post-administration of the formulations, the the animals were killed by CO 2 inhalation and the large intestine was surgically excised for evaluation of IL-10 expression and therapeutic efficacy.
Evaluation of in vivo IL-10 transgene expression
The expression of murine IL-10 upon oral administration of the plasmid in gelatin nanoparticles and NiMOS formulations in colitis-induced Balb/c mice was evaluated by quantitative RT-PCR and by measuring the protein levels using Quantikine sandwich ELISA (R&D Systems, Minneapolis, MN, USA).
Quantitative RT-PCR. Quantitative RT-PCR was performed on homogenized large intestinal tissue to determine the levels of mRNA transcript according to the published procedure. 36 The sequences of the primers used were as follows: (1) murine IL-10 1: CCAAGCCTTA TCGGAAATGA, (2) murine IL-10 2: TCTCACCCAGGG AATTCAAA, (3) murine L32 1: AGCAACAAGAAAAC CAAGCACAT and (4) murine L32 2: TTGACATTGTG GACCAGGAACT. The results obtained from the RT-PCR reaction were then analyzed by comparative C t analysis for determination of relative murine IL-10 cDNA in the samples. The PCR reaction product was then analyzed on a 1.8% agarose gel. After running the gel for 30 min at 110 V, the image was recorded under UV light and processed to visually confirm the formation of PCR product.
Oral IL-10 gene therapy for IBD MD Bhavsar and MM Amiji Murine IL-10 ELISA. Sandwich ELISA kit from R&D Systems was used to determine the levels of expressed IL-10 in the large intestine, following transfection with control and NiMOS formulations. 37 Following substrate addition, the optical density was measured at 450 nm. The IL-10 concentrations that were obtained from the ELISA experiments were then normalized to the total protein content and the values are expressed as picogram of murine IL-10 expressed per mg of total protein.
Therapeutic efficacy of locally expressed IL-10 in acute colitis model Inflammatory cytokine and chemokine profiling. The changes in pro-and anti-inflammatory cytokine concentrations upon treatment of IL-10-expressing plasmid in the large intestine was evaluated by using Q-Plex Mouse Cytokine Array ELISA kit purchased from Bio-Legend (San Diego, CA, USA). The cytokine assays were performed according to the suggested protocol. The luminescence intensity obtained for each cytokine was used to calculate the concentration of cytokines in the tissue samples using a calibration curve.
Macroscopic efficacy evaluations. Following oral administration of various control and test formulations, the macroscopic factors were reported every day until the end of the study and the colitis activity was quantified with clinical score by assessing the weight loss, stool consistency and rectal bleeding as previously described. 38 Along with the above mentioned parameters, the macroscopic efficacy evaluation also consisted colon length (in cm) and colon weight (in grams) measurements.
Microscopic efficacy evaluations. Microscopic criteria for damage and inflammation was assessed by light microscopy of hematoxylin and eosin stained histological sections obtained from tissue samples taken from a region of the inflamed colon immediately adjacent to the gross macroscopic damage. After staining, the sections were imaged using bright-field microscopy and the mucosal architectural change, cellular infiltration, external muscle thickening, presence of crypt abscess, goblet cell depletion, signs of edema, surface epithelial cell hyperplasia and signs of epithelial regeneration were assessed to qualitatively determine the degree of mucosal damage and repair in control and treated groups, respectively.
14,39
Determination of tissue MPO activity. The tissue MPO activity is a reliable index of inflammation based on the infiltration of activated neutrophils. 40 The large intestinal specimen were minced in 1.0 ml of hexadecyltrimethylammonium bromide buffer (0.5% in 50 mM phosphate buffer) on ice and homogenized. The change in absorbance upon addition of o-dianisidine hydrochloride and hydrogen peroxide was measured at 460 nm for 3 min and the values were calculated using a reported equation and normalized to a gram of tissue. 41 
Conclusions
The results of study demonstrated successful transfection at the inflammatory site in the gastrointestinal tract with murine IL-10-expressing plasmid DNA delivered orally in NiMOS. Gelatin nanoparticles, on the other hand, were not as effective in oral DNA delivery probably due to rapid degradation in the protease-and nuclease-rich gastrointestinal environment. The locally transfected IL-10 was very effective in reducing the levels of proinflammatory cytokines and chemokines, such as MCP-1 and MIP-1a, which are secreted by activated leukocytes and other tissue cells for recruitment and proliferation of macrophages and monocytes at the site of inflammation. The therapeutic benefits of transfected IL-10 were further demonstrated by gain in body weight and a significant decrease in the clinical activity score. Tissue histology also showed complete lack of cell infiltration and recovery of mucosal architecture in the treatment group. These results are highly encouraging for the potential development of oral gene therapy using NiMOS, especially for the treatment of chronic diseases such as IBD.
